{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:30:18Z","timestamp":1781839818669,"version":"3.54.5"},"reference-count":28,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Transfusion plays a main role in supportive treatment for patients who receive an allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we compare the transfusion requirements of patients undergoing different modalities of HSCT according to different time periods. The objective is to assess the evolution of HSCT transfusion requirements over time, from a single institution. Methods: The clinical charts and transfusion records of patients who underwent HSCT of different modalities at La Fe University Hospital during a twelve-year period were reviewed (2009\u20132020). For analysis, we divided the overall time into three periods: 1 from 2009 to 2012, 2 from 2013 to 2016 and 3 from 2017 to 2020. The study included 855 consecutive adult HSCT: 358 HLA-matched related donors (MRD), 134 HLA-matched unrelated donors (MUD), 223 umbilical cord blood transplantation (UCBT) and 140 haploidentical transplants (Haplo-HSCT). Results: There were no significant differences in RBC and PLT requirements or transfusion independence among the three time periods for MUD and Haplo-HSCT. However, the transfusion burden increased significantly for MRD HSCT during the 2017\u20132020 period. Conclusion: despite HSCT modalities having evolved and changed over time, overall transfusion requirements have not significantly decreased and continue to be a cornerstone of transplantation-supportive care.<\/jats:p>","DOI":"10.3390\/jcm12103467","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T02:02:11Z","timestamp":1684116131000},"page":"3467","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution"],"prefix":"10.3390","volume":"12","author":[{"given":"Pilar","family":"Solves","sequence":"first","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Marco-Ayala","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Haematology Department, University Hospital \u201cMorales Meseguer\u201d, 30007 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1489-1177","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Sanz","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-2905","authenticated-orcid":false,"given":"In\u00e9s","family":"G\u00f3mez-Segu\u00ed","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitana","family":"Balaguer-Rosell\u00f3","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Facal","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Villalba","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Montoro","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-8191","authenticated-orcid":false,"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain"},{"name":"School of Medicine and Dentistry, Catholic University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/107327481502200108","article-title":"Transfusion support issues in hematopoietic stem cell transplantation","volume":"22","author":"Cohn","year":"2015","journal-title":"Cancer Control"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.transci.2017.05.022","article-title":"Goubran Transfusion challenges in hematology oncology and hematopoietic stem cell transplant-Literature review and local experience","volume":"56","author":"Elemary","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/trf.15285","article-title":"Red blood cell product utilization in patients undergoing allogeneic stem cell transplantation","volume":"59","author":"Gastecki","year":"2019","journal-title":"Transfusion"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1537-2995.2009.02461.x","article-title":"Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: Identification of patients at risk","volume":"50","author":"Dahl","year":"2010","journal-title":"Transfusion"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5045\/br.2023.2023004","article-title":"Transfusion support in hematopoietic stem cell transplantation","volume":"58","author":"Jekarl","year":"2023","journal-title":"Blood Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/vox.13061","article-title":"International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Summary","volume":"116","author":"Solves","year":"2021","journal-title":"Vox Sang."},{"key":"ref_7","first-page":"CD004269","article-title":"Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database","volume":"4","author":"Stanworth","year":"2004","journal-title":"Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/trf.13415","article-title":"Blood transfusions and pulmonary complications after hematopoietic cell transplantation","volume":"56","author":"Solh","year":"2016","journal-title":"Transfusion"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.bbmt.2014.06.038","article-title":"Effect of CD8\u207a cell content on umbilical cord blood transplantation in adults with hematological malignancies","volume":"20","author":"Sanz","year":"2014","journal-title":"Biol. Blood Marrow. Transpl."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/bmt.2016.42","article-title":"Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS","volume":"51","author":"Sanz","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41409-020-0921-6","article-title":"Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors","volume":"55","author":"Montoro","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41409-022-01725-3","article-title":"Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"57","author":"Lazzari","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1182\/blood-2007-10-118372","article-title":"A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation","volume":"112","author":"Gajewski","year":"2008","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"8","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbmt.2010.08.017","article-title":"Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants","volume":"17","author":"Solh","year":"2011","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/sj.bmt.1705765","article-title":"Impact of ABO incompatibility on engraftment and transfusion outcome after unrelated cord blood transplantation: A single institute experience in japan","volume":"40","author":"Tomonari","year":"2007","journal-title":"Bone Marrow Transpl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/bmt.2016.264","article-title":"ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation","volume":"52","author":"Solves","year":"2017","journal-title":"Bone Marrow Transpl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/imj.12894","article-title":"Red cell and platelet transfusion burden following myeloablative allogeneic haematopoietic stem cell transplantation","volume":"45","author":"Buffery","year":"2015","journal-title":"Intern. Med. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/trf.14966","article-title":"Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993\u20132010): Factors that predict intensity and time to transfusion independence","volume":"59","author":"Griffith","year":"2019","journal-title":"Transfusion"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhang, X., Xiao, Y., Ran, Q., Liu, Y., Duan, Q., Duan, H., Ye, X., and Li, Z. (2012). Clinical observation of factors in the efficacy of blood component transfusi\u00f3n in patients following hematopoietic stem cell transplantation. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036912"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2009.08073.x","article-title":"The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative hematopoietic cell Transplantation","volume":"149","author":"Wang","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_22","first-page":"S2666","article-title":"Impact of posttransplant cyclophosphamide on transfusion requirements in hla matched sibling peripheral blood stem cell transplantation","volume":"13","author":"Sanz","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/bmt.2016.80","article-title":"Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation","volume":"51","author":"Desjonqueres","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/trf.15961","article-title":"Red blood cell and platelet transfusion support in the first 30 and 100\u2009days after allogeneic hematopoietic cell transplant","volume":"60","author":"Yuan","year":"2020","journal-title":"Transfusion"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ejh.13270","article-title":"Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation","volume":"103","author":"Solves","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"605726","DOI":"10.3389\/fimmu.2021.605726","article-title":"GVHD prophylaxis 2020","volume":"12","author":"Gooptu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1200\/JCO.19.01836","article-title":"Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial","volume":"38","author":"Tay","year":"2020","journal-title":"D. J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1111\/trf.13708","article-title":"Comparing the ratio of mean red blood cell transfusion episode rate of 1 unit versus 2 units in hematopoietic stem cell transplant patients","volume":"56","author":"Avdic","year":"2016","journal-title":"Transfusion"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3467\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:34:59Z","timestamp":1760124899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jcm12103467"],"URL":"https:\/\/doi.org\/10.3390\/jcm12103467","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]}}}